Xifaxan FDA Approval History
FDA Approved: Yes (First approved May 25, 2004)
Brand name: Xifaxan
Generic name: rifaximin
Dosage form: Tablets
Company: Salix Pharmaceuticals, Inc.
Treatment for: Traveler's Diarrhea, Hepatic Encephalopathy, Irritable Bowel Syndrome
Xifaxan (rifaximin) is a nonsystemic antibiotic indicated for the treatment of patients with traveler's diarrhea caused by noninvasive strains of Escherichia coli, to reduce the risk of recurrence of hepatic encephalopathy in patients with advanced liver disease, and for the treatment of irritable bowel syndrome with diarrhea (IBS-D).
Development timeline for Xifaxan
|May 27, 2015||Approval FDA Approves Xifaxan (rifaximin) for the Treatment of IBS-D (Irritable Bowel Syndrome with Diarrhea)|
|Mar 25, 2010||Approval FDA Approves New Use of Xifaxan for Patients with Liver Disease|
|May 25, 2004||Approval Xifaxan Salix Pharmaceuticals, Ltd - Treatment for Travelers’ Diarrhea|
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.